Quidel receives FDA clearance for AmpliVue GAS Assay Quidel announced that it has received clearance from the FDA to market its AmpliVue GAS Assay for the qualitative detection of Group A Streptococcus pyogenes nucleic acids isolated from throat swab specimens obtained from patients with signs and symptoms of pharyngitis, such as sore throat.
Quidel receives FDA clearance for Lyra molecular PCR assay Quidel announced that it has received 510k clearance from the FDA to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus viral DNA isolated from nasal swab and nasopharyngeal swab specimens. Adenovirus outbreaks can occur throughout the year, but are more common from late winter to early summer. Quidel's Lyra Adenovirus Assay is part of the new Lyra brand of ready-to-use, molecular PCR reagent kits specifically designed to be compatible with a laboratory's existing thermocycler.
Ebola in U.S. could boost flu testing, says Piper Jaffray Piper Jaffray believes the emergence of Ebola cases in the U.S. could drive incremental flu testing since the disease shares some initial symptoms with flu, likely driving people to get a test. Piper says it has increased confidence in its flu upside scenario for Quidel. It has an Overweight rating on the stock.